When looking at the antibody titer measurements of Lanz and colleagues, an ELISA test applying the described EBNA1 (AA386-405) and GlialCAM (AA370-389) peptides was used to analyse MS patients versus healthy controls within a patient collective of comparable or slightly lager sample size. This evidence concerns the gene HEPACAM and myeloid sarcoma.